title: Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.
abstract: High cancer drug prices are influenced by the availability of generic cancer drugs in a timely manner. Several strategies have been used to delay the availability of affordable generic drugs into the United States and world markets. These include reverse payment or pay-for-delay patent settlements, authorized generics, product hopping, lobbying against cross-border drug importation, buying out the competition, and others. In this forum, we detail these strategies and how they can be prevented.
authors.affiliation: Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;
authors.forename: Gregory H
authors.initials: GH
authors.lastname: Jones
authors.affiliation: Rutgers Law School, Camden, NJ;
authors.forename: Michael A
authors.initials: MA
authors.lastname: Carrier
authors.affiliation: Weill Cornell Medical Center, New York, NY; and.
authors.forename: Richard T
authors.initials: RT
authors.lastname: Silver
authors.affiliation: Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX; Baker Institute, Rice University, Houston, TX.
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
mesh_terms: D016363:Antitrust Laws; D017277:Drug Approval / Q000331:legislation & jurisprudence; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence / Q000379:methods*; D057915:Drug Substitution; D016568:Drugs, Generic / Q000191:economics / Q000600:supply & distribution*; D004465:Economic Competition; D014943:Global Health; D007356:Insurance, Pharmaceutical Services / Q000191:economics; D008119:Lobbying; D010330:Patents as Topic; D011306:Prescription Fees; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D016568:Drugs, Generic
references.citation: Health Aff (Millwood). 2013 Dec;32(12):2205-15
references.pmid: 24226092
references.citation: Issue Brief (Commonw Fund). 2015 Jan;2:1-16
references.pmid: 25807592
references.citation: Mich Law Rev. 2009 Oct;108(1):37-80
references.pmid: 20535881
references.citation: Arch Intern Med. 2012 May 14;172(9):724-30
references.pmid: 22493409
references.citation: Mayo Clin Proc. 2015 Aug;90(8):996-1000
references.pmid: 26211600
references.citation: Mayo Clin Proc. 2015 Apr;90(4):500-4
references.pmid: 25792242
references.citation: PLoS Med. 2013;10(6):e1001460
references.pmid: 23750120
references.citation: Science. 2013 Mar 22;339(6126):1386-7
references.pmid: 23520096
references.citation: JAMA Oncol. 2015 Sep;1(6):729-30
references.pmid: 26182331